IQVIA Stock Competitors

Charles River Laboratories International (NYSE:CRL) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Charles River Laboratories International has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Institutional and Insider Ownership

93.3% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 87.0% of IQVIA shares are owned by institutional investors. 1.2% of Charles River Laboratories International shares are owned by insiders. Comparatively, 1.1% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Charles River Laboratories International and IQVIA's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Charles River Laboratories International and IQVIA's gross revenue, earnings per share (EPS) and valuation.

Charles River Laboratories International has higher earnings, but lower revenue than IQVIA. IQVIA is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Charles River Laboratories International and IQVIA, as provided by MarketBeat.com.

Charles River Laboratories International currently has a consensus price target of $399.8333, suggesting a potential downside of 12.76%. IQVIA has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. Given IQVIA's stronger consensus rating and higher probable upside, analysts plainly believe IQVIA is more favorable than Charles River Laboratories International.

Exact Sciences (NASDAQ:EXAS) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings & Valuation

This table compares Exact Sciences and IQVIA's gross revenue, earnings per share (EPS) and valuation.

IQVIA has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Exact Sciences and IQVIA's net margins, return on equity and return on assets.

Volatility & Risk

Exact Sciences has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Institutional and Insider Ownership

88.3% of Exact Sciences shares are owned by institutional investors. Comparatively, 87.0% of IQVIA shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by insiders. Comparatively, 1.1% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Exact Sciences and IQVIA, as provided by MarketBeat.com.

Exact Sciences currently has a consensus price target of $151.0625, suggesting a potential upside of 57.32%. IQVIA has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. Given Exact Sciences' higher probable upside, equities analysts plainly believe Exact Sciences is more favorable than IQVIA.

Summary

IQVIA beats Exact Sciences on 10 of the 15 factors compared between the two stocks.

IQVIA (NYSE:IQV) and PPD (NASDAQ:PPD) are both large-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares IQVIA and PPD's revenue, earnings per share and valuation.

IQVIA has higher revenue and earnings than PPD. PPD is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IQVIA and PPD's net margins, return on equity and return on assets.

Risk & Volatility

IQVIA has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, PPD has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of IQVIA shares are owned by institutional investors. Comparatively, 87.9% of PPD shares are owned by institutional investors. 1.1% of IQVIA shares are owned by company insiders. Comparatively, 1.9% of PPD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for IQVIA and PPD, as provided by MarketBeat.com.

IQVIA currently has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. PPD has a consensus price target of $44.5625, suggesting a potential downside of 4.88%. Given IQVIA's stronger consensus rating and higher possible upside, research analysts plainly believe IQVIA is more favorable than PPD.

Summary

IQVIA beats PPD on 10 of the 14 factors compared between the two stocks.

IQVIA (NYSE:IQV) and Incyte (NASDAQ:INCY) are both large-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares IQVIA and Incyte's revenue, earnings per share and valuation.

IQVIA has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IQVIA and Incyte's net margins, return on equity and return on assets.

Risk & Volatility

IQVIA has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of IQVIA shares are owned by institutional investors. Comparatively, 92.0% of Incyte shares are owned by institutional investors. 1.1% of IQVIA shares are owned by company insiders. Comparatively, 15.8% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for IQVIA and Incyte, as provided by MarketBeat.com.

IQVIA currently has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. Incyte has a consensus price target of $95.3750, suggesting a potential upside of 38.22%. Given Incyte's higher possible upside, analysts plainly believe Incyte is more favorable than IQVIA.

Summary

IQVIA beats Incyte on 8 of the 14 factors compared between the two stocks.

IQVIA (NYSE:IQV) and ICON Public (NASDAQ:ICLR) are both large-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares IQVIA and ICON Public's revenue, earnings per share and valuation.

ICON Public has lower revenue, but higher earnings than IQVIA. ICON Public is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IQVIA and ICON Public's net margins, return on equity and return on assets.

Risk & Volatility

IQVIA has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, ICON Public has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of IQVIA shares are owned by institutional investors. 1.1% of IQVIA shares are owned by company insiders. Comparatively, 44.0% of ICON Public shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for IQVIA and ICON Public, as provided by MarketBeat.com.

IQVIA currently has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. ICON Public has a consensus price target of $254.50, suggesting a potential downside of 10.08%. Given IQVIA's stronger consensus rating and higher possible upside, research analysts plainly believe IQVIA is more favorable than ICON Public.

Summary

IQVIA beats ICON Public on 8 of the 14 factors compared between the two stocks.

IQVIA (NYSE:IQV) and Syneos Health (NASDAQ:SYNH) are both business services companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares IQVIA and Syneos Health's revenue, earnings per share and valuation.

IQVIA has higher revenue and earnings than Syneos Health. Syneos Health is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IQVIA and Syneos Health's net margins, return on equity and return on assets.

Risk & Volatility

IQVIA has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Syneos Health has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of IQVIA shares are owned by institutional investors. Comparatively, 97.2% of Syneos Health shares are owned by institutional investors. 1.1% of IQVIA shares are owned by company insiders. Comparatively, 0.3% of Syneos Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for IQVIA and Syneos Health, as provided by MarketBeat.com.

IQVIA currently has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. Syneos Health has a consensus price target of $90.1111, suggesting a potential downside of 6.44%. Given IQVIA's stronger consensus rating and higher possible upside, research analysts plainly believe IQVIA is more favorable than Syneos Health.

Summary

IQVIA beats Syneos Health on 11 of the 14 factors compared between the two stocks.